Henry Schein Raises 2026 Earnings Outlook as Q3 Profit Beats Forecasts and Dental Sales Grow
Henry Schein (HSIC) reported Q3 adjusted EPS of $1.56, beating estimates by $0.20, while revenue rose 4.0% to $3.47B, missing slightly. The company raised its full-year EPS guidance to $5.50–$5.56 and adjusted EBITDA growth outlook to high-single digits, driven by strong dental sales and improved profitability.
How this was made
The 30-second read
Why it matters
The key tradable update is the raised full-year adjusted EPS and adjusted EBITDA growth outlook following a Q3 adjusted EPS beat, alongside a clarification that tariff refund benefits are not expected to materially increase later in 2026.
Market read
Traders can reassess 2026 earnings expectations immediately based on the explicit guidance range and the stated drivers (dental merchandise growth, margin improvement, and tariff refund contribution).
What to watch
Investors may focus on whether the 8.6% US dental merchandise growth is sustainable and whether margin expansion can continue without additional tariff-related tailwinds.
Background
Henry Schein is a healthcare solutions provider with major dental distribution operations; the article centers on its Q3 results and updated 2026 guidance.
Ticker impact
Henry Schein reported Q3 adjusted EPS of $1.56 vs $1.36 consensus and raised full-year adjusted EPS guidance to $5.50-$5.56.
Likely upward bias as traders price in higher 2026 profitability, tempered by scrutiny of revenue shortfall and the sustainability of tariff-refund benefits.
The article contains a fresh earnings print with explicit EPS beat and a same-article full-year guidance upgrade, which are direct drivers of near-term repricing. It also flags revenue slightly below consensus and clarifies tariff refunds are not expected to materially recur, which can limit the magnitude of the reaction.
Market effects
Signals resilience in dental distribution demand and operating leverage for healthcare solutions distributors.
Primarily US-focused dental merchandise growth narrative may influence US healthcare distribution sentiment.
Global dental distribution merchandise revenue growth supports broader demand stability beyond the US.
Counterpoint
The guidance upgrade may be partly supported by tariff refund benefits already recognized, so underlying demand and margin durability could be less strong than headline EPS implies.
Key entities
- companyHenry Schein Inc.
Healthcare solutions provider reporting Q3 adjusted EPS beat and raising 2026 adjusted earnings guidance.
- personFred Lowery
CEO quoted describing momentum and US dental merchandise sales growth.
